Home > Newsletters > Drug Industry Daily > Bipartisan Bill Would Boost Exclusivity, Review Speed for Some Combo Drug Products
Drug Industry Daily
Oct. 4, 2012 | Vol. 11 No. 195
Bipartisan Bill Would Boost Exclusivity, Review Speed for Some Combo Drug Products
New fixed-dose drug combinations that include at least two INDs and target a serious or life-threatening disease could be eligible for an additional six months of marketing exclusivity and priority review under a new bipartisan-supported bill sponsored by Rep. Brian Bilbray (R-Calif.).
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.